ID   HLTF_HUMAN              Reviewed;        1009 AA.
AC   Q14527; D3DNH3; Q14536; Q16051; Q7KYJ6; Q86YA5; Q92652; Q96KM9;
DT   01-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 2.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Helicase-like transcription factor;
DE            EC=2.3.2.27;
DE            EC=3.6.4.-;
DE   AltName: Full=DNA-binding protein/plasminogen activator inhibitor 1 regulator;
DE   AltName: Full=HIP116;
DE   AltName: Full=RING finger protein 80;
DE   AltName: Full=RING-type E3 ubiquitin transferase HLTF {ECO:0000305};
DE   AltName: Full=SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3;
DE   AltName: Full=Sucrose nonfermenting protein 2-like 3;
GN   Name=HLTF; Synonyms=HIP116A, RNF80, SMARCA3, SNF2L3, ZBU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=7876228; DOI=10.1074/jbc.270.9.4575;
RA   Sheridan P.L., Schorpp M., Voz M.L., Jones K.A.;
RT   "Cloning of an SNF2/SWI2-related protein that binds specifically to
RT   the SPH motifs of the SV40 enhancer and to the HIV-1 promoter.";
RL   J. Biol. Chem. 270:4575-4587(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, ALTERNATIVE
RP   INITIATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=8672239; DOI=10.1089/dna.1996.15.429;
RA   Ding H., Descheemaeker K., Marynen P., Nelles L., Carvalho T.,
RA   Carmo-Fonseca M., Collen D., Belayew A.;
RT   "Characterization of a helicase-like transcription factor involved in
RT   the expression of the human plasminogen activator inhibitor-1 gene.";
RL   DNA Cell Biol. 15:429-442(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Ribaucour F., Wiedig M., Benotmane A.M., Coppee F., Belayew A.;
RT   "Characterization of the human SMARCA3/HLTF gene.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-213.
RX   PubMed=8342330;
RA   Descheemaeker K.;
RT   "On the regulation of the plasminogen activator inhibitor-1 gene
RT   expression.";
RL   Verh. K. Acad. Geneeskd. Belg. 55:225-264(1993).
RN   [7]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=9126292; DOI=10.1006/dbio.1996.8486;
RA   Gong X., Kaushal S., Ceccarelli E., Bogdanova N., Neville C.,
RA   Nguyen T., Clark H., Khatib Z.A., Valentine M., Look A.T.,
RA   Rosenthal N.;
RT   "Developmental regulation of Zbu1, a DNA-binding member of the
RT   SWI2/SNF2 family.";
RL   Dev. Biol. 183:166-182(1997).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH SP1 AND SP3.
RX   PubMed=10391891; DOI=10.1074/jbc.274.28.19573;
RA   Ding H., Benotmane A.M., Suske G., Collen D., Belayew A.;
RT   "Functional interactions between Sp1 or Sp3 and the helicase-like
RT   transcription factor mediate basal expression from the human
RT   plasminogen activator inhibitor-1 gene.";
RL   J. Biol. Chem. 274:19573-19580(1999).
RN   [9]
RP   EPIGENETIC INACTIVATION IN COLON CANCER.
RX   PubMed=11904375; DOI=10.1073/pnas.062459899;
RA   Moinova H.R., Chen W.-D., Shen L., Smiraglia D., Olechnowicz J.,
RA   Ravi L., Kasturi L., Myeroff L., Plass C., Parsons R., Minna J.,
RA   Willson J.K.V., Green S.B., Issa J.-P., Markowitz S.D.;
RT   "HLTF gene silencing in human colon cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:4562-4567(2002).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-397; SER-398; SER-400
RP   AND THR-736, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, AND INTERACTION WITH PCNA;
RP   UBE2N AND RAD18.
RX   PubMed=18316726; DOI=10.1073/pnas.0800563105;
RA   Unk I., Hajdu I., Fatyol K., Hurwitz J., Yoon J.-H., Prakash L.,
RA   Prakash S., Haracska L.;
RT   "Human HLTF functions as a ubiquitin ligase for proliferating cell
RT   nuclear antigen polyubiquitination.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3768-3773(2008).
RN   [13]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, AND INTERACTION WITH PCNA;
RP   RAD18; SHPRH AND UBE2N.
RX   PubMed=18719106; DOI=10.1073/pnas.0805685105;
RA   Motegi A., Liaw H.-J., Lee K.-Y., Roest H.P., Maas A., Wu X.,
RA   Moinova H., Markowitz S.D., Ding H., Hoeijmakers J.H.J., Myung K.;
RT   "Polyubiquitination of proliferating cell nuclear antigen by HLTF and
RT   SHPRH prevents genomic instability from stalled replication forks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12411-12416(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION AT TYR-195.
RX   PubMed=21457752; DOI=10.1016/j.mce.2011.03.009;
RA   Helmer R.A., Dertien J.S., Chilton B.S.;
RT   "Prolactin induces Jak2 phosphorylation of RUSHY195.";
RL   Mol. Cell. Endocrinol. 338:79-83(2011).
RN   [18]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-27, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [19]
RP   STRUCTURE BY NMR OF 51-171.
RG   Structural genomics consortium (SGC);
RT   "NMR structure of the HLTF hiran domain.";
RL   Submitted (OCT-2010) to the PDB data bank.
CC   -!- FUNCTION: Has both helicase and E3 ubiquitin ligase activities.
CC       Possesses intrinsic ATP-dependent nucleosome-remodeling activity;
CC       This activity may be required for transcriptional activation or
CC       repression of specific target promoters (By similarity). These may
CC       include the SERPINE1 and HIV-1 promoters and the SV40 enhancer, to
CC       which this protein can bind directly. Plays a role in error-free
CC       postreplication repair (PRR) of damaged DNA and maintains genomic
CC       stability through acting as a ubiquitin ligase for 'Lys-63'-linked
CC       polyubiquitination of chromatin-bound PCNA. {ECO:0000250,
CC       ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:18316726,
CC       ECO:0000269|PubMed:18719106, ECO:0000269|PubMed:7876228,
CC       ECO:0000269|PubMed:8672239, ECO:0000269|PubMed:9126292}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with SP1 and SP3 independently of DNA; the
CC       interaction with these transcriptional factors may be required for
CC       basal transcription of target genes. Interacts with EGR1; the
CC       interaction requires prior binding to DNA and represses c-Rel via
CC       a DNA looping mechanism (By similarity). Interacts with GATA4 (By
CC       similarity). Interacts with PCNA; the interaction promotes
CC       polyubiquitination of PCNA through association with the UBE2B-
CC       RAD18 and UBE2V2-UBE2N ubiquitin ligase complexes. Interacts with
CC       RAD18, SHPRH, UBE2V2 and UBE2N. {ECO:0000250,
CC       ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:18316726,
CC       ECO:0000269|PubMed:18719106}.
CC   -!- INTERACTION:
CC       P60903:S100A10; NbExp=2; IntAct=EBI-1045161, EBI-717048;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:8672239}. Nucleus, nucleolus {ECO:0000250}.
CC       Nucleus, nucleoplasm {ECO:0000250}. Note=Nuclear localization is
CC       stimulated by progesterone. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14527-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14527-2; Sequence=VSP_018873;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, heart, kidney, liver,
CC       lung, pancreas, placenta and skeletal muscle.
CC       {ECO:0000269|PubMed:8672239, ECO:0000269|PubMed:9126292}.
CC   -!- MISCELLANEOUS: Subject to frequent epigenetic inactivation by
CC       promoter methylation in colon cancer.
CC   -!- SIMILARITY: Belongs to the SNF2/RAD54 helicase family. RAD16
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: In contrast with other SMARC proteins, there is currently
CC       no evidence that it associates with actin or actin-related
CC       proteins. It may rather act as a sequence-specific DNA binding
CC       ATPase, whose precise function remains to be fully characterized.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HLTFID42332ch3q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L34673; AAA67436.1; -; mRNA.
DR   EMBL; Z46606; CAA86571.1; -; mRNA.
DR   EMBL; Z46606; CAA86572.1; -; mRNA.
DR   EMBL; AJ418064; CAD10805.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78889.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78892.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78893.1; -; Genomic_DNA.
DR   EMBL; BC044659; AAH44659.1; -; mRNA.
DR   EMBL; S64671; AAB27691.1; -; mRNA.
DR   CCDS; CCDS33875.1; -. [Q14527-1]
DR   PIR; S49618; S49618.
DR   RefSeq; NP_001305863.1; NM_001318934.1.
DR   RefSeq; NP_001305864.1; NM_001318935.1. [Q14527-1]
DR   RefSeq; NP_003062.2; NM_003071.3. [Q14527-1]
DR   RefSeq; NP_620636.1; NM_139048.2. [Q14527-1]
DR   RefSeq; XP_016862568.1; XM_017007079.1.
DR   UniGene; Hs.3068; -.
DR   PDB; 2MZN; NMR; -; A=51-171.
DR   PDB; 4HRE; X-ray; 2.79 A; G/H/K/L=26-39.
DR   PDB; 4HRH; X-ray; 3.00 A; C/D=26-39.
DR   PDB; 4S0N; X-ray; 1.50 A; A/B/C/D=55-180.
DR   PDB; 4XZF; X-ray; 1.38 A; A=58-174.
DR   PDB; 4XZG; X-ray; 2.40 A; A/B/C/D/E/F/G/H/I=57-174.
DR   PDB; 5BNH; X-ray; 1.70 A; A/D=55-175.
DR   PDB; 5K5F; NMR; -; A=51-171.
DR   PDBsum; 2MZN; -.
DR   PDBsum; 4HRE; -.
DR   PDBsum; 4HRH; -.
DR   PDBsum; 4S0N; -.
DR   PDBsum; 4XZF; -.
DR   PDBsum; 4XZG; -.
DR   PDBsum; 5BNH; -.
DR   PDBsum; 5K5F; -.
DR   ProteinModelPortal; Q14527; -.
DR   SMR; Q14527; -.
DR   BioGrid; 112480; 55.
DR   DIP; DIP-29828N; -.
DR   IntAct; Q14527; 24.
DR   MINT; MINT-1639589; -.
DR   STRING; 9606.ENSP00000308944; -.
DR   iPTMnet; Q14527; -.
DR   PhosphoSitePlus; Q14527; -.
DR   BioMuta; HLTF; -.
DR   DMDM; 60390864; -.
DR   EPD; Q14527; -.
DR   MaxQB; Q14527; -.
DR   PaxDb; Q14527; -.
DR   PeptideAtlas; Q14527; -.
DR   PRIDE; Q14527; -.
DR   DNASU; 6596; -.
DR   Ensembl; ENST00000310053; ENSP00000308944; ENSG00000071794. [Q14527-1]
DR   Ensembl; ENST00000392912; ENSP00000376644; ENSG00000071794. [Q14527-1]
DR   Ensembl; ENST00000494055; ENSP00000420429; ENSG00000071794. [Q14527-1]
DR   GeneID; 6596; -.
DR   KEGG; hsa:6596; -.
DR   UCSC; uc003ewq.2; human. [Q14527-1]
DR   CTD; 6596; -.
DR   DisGeNET; 6596; -.
DR   GeneCards; HLTF; -.
DR   H-InvDB; HIX0024319; -.
DR   HGNC; HGNC:11099; HLTF.
DR   HPA; HPA015284; -.
DR   HPA; HPA049001; -.
DR   MIM; 603257; gene.
DR   neXtProt; NX_Q14527; -.
DR   OpenTargets; ENSG00000071794; -.
DR   PharmGKB; PA35949; -.
DR   eggNOG; KOG1001; Eukaryota.
DR   eggNOG; COG0553; LUCA.
DR   GeneTree; ENSGT00860000133889; -.
DR   HOVERGEN; HBG079192; -.
DR   InParanoid; Q14527; -.
DR   KO; K15711; -.
DR   OMA; NDDAMKL; -.
DR   OrthoDB; EOG091G013T; -.
DR   PhylomeDB; Q14527; -.
DR   TreeFam; TF332703; -.
DR   SIGNOR; Q14527; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; HLTF; human.
DR   GeneWiki; HLTF; -.
DR   GenomeRNAi; 6596; -.
DR   PRO; PR:Q14527; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000071794; -.
DR   CleanEx; HS_HLTF; -.
DR   ExpressionAtlas; Q14527; baseline and differential.
DR   Genevisible; Q14527; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATPase activity; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:InterPro.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0006301; P:postreplication repair; IEA:InterPro.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR014905; HIRAN.
DR   InterPro; IPR030065; HLTF.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000330; SNF2_N.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR10799:SF915; PTHR10799:SF915; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF08797; HIRAN; 1.
DR   Pfam; PF00176; SNF2_N; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00910; HIRAN; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF52540; SSF52540; 4.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative initiation; ATP-binding;
KW   Chromatin regulator; Complete proteome; Cytoplasm; DNA-binding;
KW   Helicase; Hydrolase; Metal-binding; Methylation;
KW   Multifunctional enzyme; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transcription; Transferase;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1   1009       Helicase-like transcription factor.
FT                                /FTId=PRO_0000030722.
FT   DOMAIN      435    606       Helicase ATP-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00541}.
FT   DOMAIN      837    996       Helicase C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00542}.
FT   DNA_BIND     38    287
FT   NP_BIND     294    301       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00541}.
FT   ZN_FING     760    801       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION      925   1009       Interaction with SP1 and SP3.
FT                                {ECO:0000269|PubMed:10391891}.
FT   MOTIF       557    560       DEGH box.
FT   MOD_RES      27     27       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     195    195       Phosphotyrosine; by JAK2.
FT                                {ECO:0000269|PubMed:21457752}.
FT   MOD_RES     397    397       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     398    398       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     400    400       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     736    736       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VAR_SEQ       1    122       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8672239}.
FT                                /FTId=VSP_018873.
FT   VARIANT     311    311       N -> S (in dbSNP:rs2305868).
FT                                /FTId=VAR_052121.
FT   VARIANT     362    362       E -> Q (in dbSNP:rs2228257).
FT                                /FTId=VAR_052122.
FT   VARIANT     819    819       R -> H (in dbSNP:rs2229361).
FT                                /FTId=VAR_029265.
FT   CONFLICT     35     35       P -> L (in Ref. 2; CAA86571).
FT                                {ECO:0000305}.
FT   CONFLICT    211    213       KTE -> PEF (in Ref. 6; AAB27691).
FT                                {ECO:0000305}.
FT   CONFLICT    337    337       D -> G (in Ref. 2; CAA86571/CAA86572 and
FT                                3; CAD10805). {ECO:0000305}.
FT   CONFLICT    382    382       S -> T (in Ref. 1; AAA67436).
FT                                {ECO:0000305}.
FT   CONFLICT    429    429       Missing (in Ref. 5; AAH44659).
FT                                {ECO:0000305}.
FT   CONFLICT    913    913       K -> R (in Ref. 2; CAA86571/CAA86572 and
FT                                3; CAD10805). {ECO:0000305}.
FT   HELIX        51     54       {ECO:0000244|PDB:2MZN}.
FT   STRAND       58     68       {ECO:0000244|PDB:4XZF}.
FT   HELIX        70     72       {ECO:0000244|PDB:4XZF}.
FT   STRAND       81     87       {ECO:0000244|PDB:4XZF}.
FT   STRAND       98    101       {ECO:0000244|PDB:4XZF}.
FT   STRAND      107    111       {ECO:0000244|PDB:4XZF}.
FT   HELIX       113    124       {ECO:0000244|PDB:4XZF}.
FT   STRAND      129    134       {ECO:0000244|PDB:4XZF}.
FT   STRAND      141    152       {ECO:0000244|PDB:4XZF}.
FT   HELIX       154    156       {ECO:0000244|PDB:4XZF}.
FT   HELIX       157    166       {ECO:0000244|PDB:4XZF}.
SQ   SEQUENCE   1009 AA;  113929 MW;  0AB96F6C8484FD15 CRC64;
     MSWMFKRDPV WKYLQTVQYG VHGNFPRLSY PTFFPRFEFQ DVIPPDDFLT SDEEVDSVLF
     GSLRGHVVGL RYYTGVVNNN EMVALQRDPN NPYDKNAIKV NNVNGNQVGH LKKELAGALA
     YIMDNKLAQI EGVVPFGANN AFTMPLHMTF WGKEENRKAV SDQLKKHGFK LGPAPKTLGF
     NLESGWGSGR AGPSYSMPVH AAVQMTTEQL KTEFDKLFED LKEDDKTHEM EPAEAIETPL
     LPHQKQALAW MVSRENSKEL PPFWEQRNDL YYNTITNFSE KDRPENVHGG ILADDMGLGK
     TLTAIAVILT NFHDGRPLPI ERVKKNLLKK EYNVNDDSMK LGGNNTSEKA DGLSKDASRC
     SEQPSISDIK EKSKFRMSEL SSSRPKRRKT AVQYIESSDS EEIETSELPQ KMKGKLKNVQ
     SETKGRAKAG SSKVIEDVAF ACALTSSVPT TKKKMLKKGA CAVEGSKKTD VEERPRTTLI
     ICPLSVLSNW IDQFGQHIKS DVHLNFYVYY GPDRIREPAL LSKQDIVLTT YNILTHDYGT
     KGDSPLHSIR WLRVILDEGH AIRNPNAQQT KAVLDLESER RWVLTGTPIQ NSLKDLWSLL
     SFLKLKPFID REWWHRTIQR PVTMGDEGGL RRLQSLIKNI TLRRTKTSKI KGKPVLELPE
     RKVFIQHITL SDEERKIYQS VKNEGRATIG RYFNEGTVLA HYADVLGLLL RLRQICCHTY
     LLTNAVSSNG PSGNDTPEEL RKKLIRKMKL ILSSGSDEEC AICLDSLTVP VITHCAHVFC
     KPCICQVIQN EQPHAKCPLC RNDIHEDNLL ECPPEELARD SEKKSDMEWT SSSKINALMH
     ALTDLRKKNP NIKSLVVSQF TTFLSLIEIP LKASGFVFTR LDGSMAQKKR VESIQCFQNT
     EAGSPTIMLL SLKAGGVGLN LSAASRVFLM DPAWNPAAED QCFDRCHRLG QKQEVIITKF
     IVKDSVEENM LKIQNKKREL AAGAFGTKKP NADEMKQAKI NEIRTLIDL
//
